Phase III ALUR study supports the use of Roche ’s Alecensa for people with advanced ALK-positive lung cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III ALUR study met its primary endpoint, demonstrating that Alecensa ® (alectinib) significantly improved progression-free survival (PFS) in people with anaplastic lymphoma kinase (ALK)-positive advanced (metastatic) non-small cell lung cancer (NSCLC) who had progressed following treatment with one prior line of both platinum-based chemotherapy and crizotinib, compa red with chemotherapy.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news